T he D (Rh1) antigen is one of the most clinically significant blood group antigens. It is involved in transfusion and fetomaternal incompatibilities. Several hundred alleles have now been described for the RHD gene. 1 Some are associated with an alloimmunization risk for their carrier (partial antigen), whereas others are not (weak antigen).
BRIEF METHODS
Weakened D antigen expression (11 samples), unexplained mixed-field agglutination for the RhD antigen (one sample), or the discovery of anti-D in RH:1 patients (two samples) prompted the molecular analysis of the RHD gene. DNA sequencing of RHD Exons 1 through 10 was performed by the Sanger dideoxy method using a cycle-sequencing kit (Big Dye Terminator v3.1; ThermoFisher) and a genetic analyzer (3500Dx; ThermoFisher) according to the manufacturer's protocol and as previously published. 2 Because the novel alleles described are very rare compared with RHD deletion, zygosity testing was not performed, hemizygosity being the most likely situation.
Fresh red blood cells (RBCs) were not available for serologic studies. The probands' transfusion and alloimmunization histories were sought.
RESULTS
The results are summarized in Table 1 . Both probands carrying the RHD*841C allele had D antibodies, but fresh RBCs were not available for adsorption techniques. Because normal RHD was present in trans for these patients, the D antibodies were probably autoantibodies. These two probands were the only ones with a transfusion history. They had received two and eight units of D-positive packed RBCs, respectively. No other proband had or was known to have Rh antibodies.
As a precaution, we suggest that several of the novel alleles described in this report should be considered to produce partial RhD proteins. First, the point mutations of alleles RHD*119G, RHD*149A, RHD*691T, 692T, and RHD*871T are predicted to cause amino acid substitutions in extracellular domains and thus are exposed at the RBC membrane. Second, the allele RHD*394C is closely related to previously described alleles RHD*394A and RHD*395A, both of which are considered to produce partial RhD proteins. 3 This should be confirmed by serologic studies when fresh RBCs become available. The novel alleles RHD*594T, 602G, 667G, and 819A and RHD*602G, 667G, 819A, and 1063A may be considered part of the weak D type 4 cluster, because they carry the mutations associated with weak D type 4.0 4 and one additional point mutation each, in Positions 594 and 1063, respectively.
BRIEF SUMMARY
This report describes 13 novel RHD alleles that were predicted by serological elements and confirmed by exon genotyping. aa 5 amino acid; NT 5 not tested; w 5 weak antigen expression; dp 5 unexplained mixed-field agglutination; NA 5 not available.
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